Health Care/Hospital

Amplicore, Inc. Announces Closing of a Successful $4M Seed Funding Round

CINCINNATI, March 26, 2021 /PRNewswire/ -- Amplicore Inc., an early-stage biopharmaceutical company currently developing locally delivered and minimally invasive therapeutic solutions for musculoskeletal diseases, has successfully closed its Series Seed round of funding at$4 million. Investments ...

2021-03-26 05:19 2787

Antengene Appoints Kevin Lynch as Chief Medical Officer

SHANGHAI, China and MELBOURNE, Australia, March 25, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing, and commercializing global first-in-class and/or best-in-class therapeutics in ...

2021-03-25 23:26 3057

Antengene Appoints Bo Shan as Chief Scientific Officer

SHANGHAI, March 25, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing, and commercializing global first-in-class and/or best-in-class therapeutics in hematology and oncology, announc...

2021-03-25 22:36 3213

CStone Pharmaceuticals Reports Financial Results and Business Highlights for Full-year 2020

SUZHOU, China, March 25, 2021 /PRNewswire/ -- CStone Pharmaceuticals (CStone, HKEX: 2616), a leading biopharmaceutical company focused on developing and commercializing innovative immuno-oncology therapies and precision medicines, today reported financial results and business highlights for the f...

2021-03-25 22:03 3877

SOPHiA GENETICS and Hitachi Announce Collaboration to Advance Data Driven Precision Medicine

Multi-year agreement to expand commercial footprint with world-leading genomics platform and develop R&D to unlock the potential of multimodal health data BOSTON, LAUSANNE, Switzerland and TOKYO, March 25, 2021 /PRNewswire/ -- SOPHiA GENETICS SA ("SOPHiA GENETICS"), pioneer in Data-Driven Medicin...

2021-03-25 21:00 4561

Össur Recognized by World Intellectual Property Organization (WIPO) as Leading Assistive Technology Development

REYKJAVIK, Iceland, March 25, 2021 /PRNewswire/ -- Össur (Nasdaq: OSSR), a global leader in the orthotics and prosthetics (O&P) industry with a rich history of ground-breaking innovations, has been recognized by the World Intellectual Property Organization (WIPO) for its intellectual property le...

2021-03-25 20:55 1606

BioNTech Chairman Helmut Jeggle joins the Board of IQM Quantum Computers

MUNICH, March 25, 2021 /PRNewswire/ -- IQM Quantum Computers  (IQM) announced today that Helmut Jeggle has joined IQM´s board of directors. He joins the company during a transformational phase. After successfully closing its Series A funding round and selling its first q...

2021-03-25 18:29 2531

AllianThera Biopharma comes out of stealth and collaborates on AI with Insilico Medicine

AllianThera Biopharma led by ex-pharma veterans, Dr. Yuan-Hua Ding and Dr. Javier Cote-Sierra partnered with an AI-driven drug discovery company, Insilico Medicine to tackle cancer and autoimmune diseases SUZHOU, China, March 25, 2021 /PRNewswire/ -- Today, AllianThera Biopharma (ATB), a Suzhou,...

2021-03-25 17:00 2360

GenScript Signs a Strategic Partnership with the Theragen Etex and MedPACTO for Therapeutic Antibody Drug development

SINGAPORE, March 25, 2021 /PRNewswire/ -- A global leading biotech company GenScript Biotech Corporation ("GenScript", Stock Code: 1548.HK) announced that the Company has entered into a strategic partnership with the Theragen Etex, a South Korea-based comprehensive pharmaceutical and biotechnology...

2021-03-25 16:35 3407

Nippon Express Obtains IATA CEIV Pharma Certification for Temperature-controlled Facility near Narita Airport

TOKYO, March 25, 2021 /PRNewswire/ -- Nippon Express Co., Ltd. has obtained IATA CEIV Pharma (*) pharmaceutical transport quality certification for its Narita Temperature-Controlled Hub (NTCH) and for transport operations between NTCH and Narita Airport, effectiveMarch 15. This is the second pha...

2021-03-25 15:00 2060

No COVID slump as majority of Australians satisfied with healthcare system new Australian Healthcare Index reports

MELBOURNE and PERTH, Australia, March 25, 2021 /PRNewswire/ -- Despite a once-in-a-century pandemic still lingering one year on, Australians have given a vote of confidence to the Australian healthcare system with 65.5% rating it a score of 8 or above out of 10 in a new report, produced by the Au...

2021-03-25 03:00 1595

Positive Phase III Clinical Results for EirGenix's Proposed Trastuzumab Biosimilar

TAIPEI, March 24, 2021 /PRNewswire/ -- In a press conference today, EirGenix, Inc. (6589.TT) announced that the Phase III clinical trial (Trial No.: EGC002, NCT03433313) of its breast cancer biosimilar, EG12014 (proposed trastuzumab biosimilar, also called EGI014), has met its primary endpoint. E...

2021-03-24 23:27 2858

Ping An and Zhongshan Hospital to Collaborate on "Healthcare + Finance + Technology" Innovations

HONG KONG and SHANGHAI, March 24, 2021 /PRNewswire/ -- Ping An Insurance (Group) Company ofChina, Ltd. (hereafter "Ping An" or the "Group", HKEX: 2318; SSE: 601318) has signed a strategic cooperation agreement with Zhongshan Hospital, which is affiliated with Fudan University inShanghai. The two ...

2021-03-24 20:15 5543

Fishawack Health unveils an unrivaled global market access and HEOR offering with the acquisition of PRMA Consulting

Fishawack Health bolsters its strong strategic offering by acquiring PRMA Consulting – a global market access and HEOR consulting leader with significant  expertise in US, EU, and Asia-Pacific markets LONDON, March 24, 2021 /PRNewswire/ -- Leading life science commercialization partnerFishawack H...

2021-03-24 20:00 1739

Ascentage Pharma's First Third-Generation BCR-ABL Inhibitor in China Olverembatinib (HQP1351) Recommended for Breakthrough Therapy Designation

SUZHOU, China and ROCKVILLE, Md., March 24, 2021 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that the Center for Drug Ev...

2021-03-24 19:07 1617

LimaCorporate And HSS Partner To Open First Provider-based Design And 3D Printing Center For Complex Joint Reconstruction Surgery

SAN DANIELE DEL FRIULI, Italy, March 24, 2021 /PRNewswire/ -- LimaCorporate  S.p.A., (Lima) leading global orthopedics manufacturer, andHospital for Special Surgery (HSS), top-ranked in orthopedics for 11 consecutive years in the U.S., byU.S. New...

2021-03-24 16:00 1843

Clover Biopharmaceuticals and Dynavax Announce First Participants Dosed in SPECTRA, a Global Phase 2/3 Clinical Trial for Adjuvanted S-Trimer COVID-19 Vaccine Candidate

* Over 22,000 participants aged 18 years or older are expected to be enrolled in SPECTRA acrossLatin America, Asia, Europe and Africa * Interim analysis of the primary endpoint expected in the middle of 2021 CHENGDU, China and EMERYVILLE, Calif., March 24, 2021 /PRNewswire/ -- Clover Biopharm...

2021-03-24 14:18 2896

Forest Hills Lab is filing an IND to initiate a clinical phase 2 study on Parkinson's disease with the US FDA

HONG KONG, March 23, 2021 /PRNewswire/ -- Forest Hills Partners Hong Kong Limited (also known as Forest Hills Lab) is ready to file an Investigative New Drug (IND) application with the US FDA inApril 2021 to assess tolerability and efficacy with one of its drug candidates, namely FHL-301 in a pha...

2021-03-24 12:25 5115

Mindray Releases New Ceiling Supply Unit, Creating a More Optimized ICU Environment

SHENZHEN, China, March 24, 2021 /PRNewswire/ -- Mindray (SZSE: 300760), a global leader in developing and providing medical devices, has released a new series of ceiling supply units which exceeds ISO 11197-2019 standards. The HyPort R80 is the newest generation of bedside device management syste...

2021-03-24 11:49 1714

CStone Announces New Drug Approval of GAVRETO(R) (pralsetinib) as First Selective RET Inhibitor in China, Providing a New Therapy for a Subset of Non-Small Cell Lung Cancer Patients

* GAVRETO has been approved for the treatment of adults with locally advanced or metastatic RET fusion-positive non-small cell lung cancer after platinum-based chemotherapy * GAVRETO is the first approved selective RET inhibitor in China and first approved precision therapy for CStone SUZHOU,...

2021-03-24 10:46 4786
1 ... 354355356357358359360 ... 554

Week's Top Stories